Tapasztalataink a rekombináns faktor VIIa-val (NovoSeven) a magas kockázatú szívmutétek vérzéses szövodményeinek kezelésében.

Translated title of the contribution: Our experience with recombinant activated factor VII (NovoSeven) in the high risk cardiosurgical patients with bleeding complication

Szabolcs Miskolczi, Miklós Vaszily, C. Papp, Arpád Péterffy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Haemorrhagic complications significantly increase mortality and cost of treatment in cardiac surgery. A few years ago recombinant activated factor VII has been introduced to decrease such complications. In our department recombinant activated factor VII has been used in 11 patients between 2004 and 2007. Nine of them underwent a combined (simultaneous CABG and valve replacement) high risk surgery with long aortic cross clamp time and long extracorporeal circulation time. One patient underwent a repeat coronary artery bypass operation and one was operated for aortic dissection. The average dose given was 6.5 mg (2.4-9.6 mg). The average amount of bleeding without NovoSeven given was 5440 ml, however it was only 987 ml when NovoSeven was used. Nine of the patients were completely recovered and discharged from hospital, but two of them died in the postoperative period for delayed use of the recombinant factor VII-a and for severe co-morbidities (bowel ischaemia, cirrhosis of the liver). NovoSeven given in the proper time and dose significantly reduces bleeding following cardiac surgery, even if it cannot be stopped surgically. Using recombinant factor VIIa can save life in case of severe non-surgical diffuse bleeding or in case of suture insufficiency caused by friable soft tissues following high risk combined surgery with extremely long aortic cross clamp time and extracorporeal circulation time. Significant delay in the use of NovoSeven should be avoided because the temporary reduction of bleeding usually does not change fatal outcome.

Original languageHungarian
Pages (from-to)45-47
Number of pages3
JournalMagyar sebészet
Volume61 Suppl
DOIs
Publication statusPublished - 2008

Fingerprint

Factor VIIa
Hemorrhage
Extracorporeal Circulation
Thoracic Surgery
Factor VII
Fatal Outcome
Postoperative Period
Coronary Artery Bypass
Liver Cirrhosis
Health Care Costs
Sutures
Dissection
Ischemia
recombinant FVIIa
Morbidity
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tapasztalataink a rekombináns faktor VIIa-val (NovoSeven) a magas kockázatú szívmutétek vérzéses szövodményeinek kezelésében. / Miskolczi, Szabolcs; Vaszily, Miklós; Papp, C.; Péterffy, Arpád.

In: Magyar sebészet, Vol. 61 Suppl, 2008, p. 45-47.

Research output: Contribution to journalArticle

@article{674dca20040f496fb783aea1d5b89e8e,
title = "Tapasztalataink a rekombin{\'a}ns faktor VIIa-val (NovoSeven) a magas kock{\'a}zat{\'u} sz{\'i}vmut{\'e}tek v{\'e}rz{\'e}ses sz{\"o}vodm{\'e}nyeinek kezel{\'e}s{\'e}ben.",
abstract = "Haemorrhagic complications significantly increase mortality and cost of treatment in cardiac surgery. A few years ago recombinant activated factor VII has been introduced to decrease such complications. In our department recombinant activated factor VII has been used in 11 patients between 2004 and 2007. Nine of them underwent a combined (simultaneous CABG and valve replacement) high risk surgery with long aortic cross clamp time and long extracorporeal circulation time. One patient underwent a repeat coronary artery bypass operation and one was operated for aortic dissection. The average dose given was 6.5 mg (2.4-9.6 mg). The average amount of bleeding without NovoSeven given was 5440 ml, however it was only 987 ml when NovoSeven was used. Nine of the patients were completely recovered and discharged from hospital, but two of them died in the postoperative period for delayed use of the recombinant factor VII-a and for severe co-morbidities (bowel ischaemia, cirrhosis of the liver). NovoSeven given in the proper time and dose significantly reduces bleeding following cardiac surgery, even if it cannot be stopped surgically. Using recombinant factor VIIa can save life in case of severe non-surgical diffuse bleeding or in case of suture insufficiency caused by friable soft tissues following high risk combined surgery with extremely long aortic cross clamp time and extracorporeal circulation time. Significant delay in the use of NovoSeven should be avoided because the temporary reduction of bleeding usually does not change fatal outcome.",
author = "Szabolcs Miskolczi and Mikl{\'o}s Vaszily and C. Papp and Arp{\'a}d P{\'e}terffy",
year = "2008",
doi = "10.1556/MaSeb.61.2008.Suppl.11",
language = "Hungarian",
volume = "61 Suppl",
pages = "45--47",
journal = "Magyar Sebeszet",
issn = "0025-0295",
publisher = "Ifjusagi Lapkiado Vallalat",

}

TY - JOUR

T1 - Tapasztalataink a rekombináns faktor VIIa-val (NovoSeven) a magas kockázatú szívmutétek vérzéses szövodményeinek kezelésében.

AU - Miskolczi, Szabolcs

AU - Vaszily, Miklós

AU - Papp, C.

AU - Péterffy, Arpád

PY - 2008

Y1 - 2008

N2 - Haemorrhagic complications significantly increase mortality and cost of treatment in cardiac surgery. A few years ago recombinant activated factor VII has been introduced to decrease such complications. In our department recombinant activated factor VII has been used in 11 patients between 2004 and 2007. Nine of them underwent a combined (simultaneous CABG and valve replacement) high risk surgery with long aortic cross clamp time and long extracorporeal circulation time. One patient underwent a repeat coronary artery bypass operation and one was operated for aortic dissection. The average dose given was 6.5 mg (2.4-9.6 mg). The average amount of bleeding without NovoSeven given was 5440 ml, however it was only 987 ml when NovoSeven was used. Nine of the patients were completely recovered and discharged from hospital, but two of them died in the postoperative period for delayed use of the recombinant factor VII-a and for severe co-morbidities (bowel ischaemia, cirrhosis of the liver). NovoSeven given in the proper time and dose significantly reduces bleeding following cardiac surgery, even if it cannot be stopped surgically. Using recombinant factor VIIa can save life in case of severe non-surgical diffuse bleeding or in case of suture insufficiency caused by friable soft tissues following high risk combined surgery with extremely long aortic cross clamp time and extracorporeal circulation time. Significant delay in the use of NovoSeven should be avoided because the temporary reduction of bleeding usually does not change fatal outcome.

AB - Haemorrhagic complications significantly increase mortality and cost of treatment in cardiac surgery. A few years ago recombinant activated factor VII has been introduced to decrease such complications. In our department recombinant activated factor VII has been used in 11 patients between 2004 and 2007. Nine of them underwent a combined (simultaneous CABG and valve replacement) high risk surgery with long aortic cross clamp time and long extracorporeal circulation time. One patient underwent a repeat coronary artery bypass operation and one was operated for aortic dissection. The average dose given was 6.5 mg (2.4-9.6 mg). The average amount of bleeding without NovoSeven given was 5440 ml, however it was only 987 ml when NovoSeven was used. Nine of the patients were completely recovered and discharged from hospital, but two of them died in the postoperative period for delayed use of the recombinant factor VII-a and for severe co-morbidities (bowel ischaemia, cirrhosis of the liver). NovoSeven given in the proper time and dose significantly reduces bleeding following cardiac surgery, even if it cannot be stopped surgically. Using recombinant factor VIIa can save life in case of severe non-surgical diffuse bleeding or in case of suture insufficiency caused by friable soft tissues following high risk combined surgery with extremely long aortic cross clamp time and extracorporeal circulation time. Significant delay in the use of NovoSeven should be avoided because the temporary reduction of bleeding usually does not change fatal outcome.

UR - http://www.scopus.com/inward/record.url?scp=58149265450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149265450&partnerID=8YFLogxK

U2 - 10.1556/MaSeb.61.2008.Suppl.11

DO - 10.1556/MaSeb.61.2008.Suppl.11

M3 - Article

C2 - 18504237

AN - SCOPUS:58149265450

VL - 61 Suppl

SP - 45

EP - 47

JO - Magyar Sebeszet

JF - Magyar Sebeszet

SN - 0025-0295

ER -